Your browser doesn't support javascript.
loading
Clinical Outcomes of Online Adaptive Magnetic Resonance-Guided Stereotactic Body Radiotherapy of Adrenal Metastases from a Single Institution.
Hoegen-Saßmannshausen, Philipp; Jessen, Inga; Buchele, Carolin; Schlüter, Fabian; Rippke, Carolin; Renkamp, Claudia Katharina; Weykamp, Fabian; Regnery, Sebastian; Liermann, Jakob; Meixner, Eva; Hoeltgen, Line; Eichkorn, Tanja; König, Laila; Debus, Jürgen; Klüter, Sebastian; Hörner-Rieber, Juliane.
Afiliación
  • Hoegen-Saßmannshausen P; Department of Radiation Oncology, Heidelberg University Hospital, 69120 Heidelberg, Germany.
  • Jessen I; Heidelberg Institute of Radiation Oncology (HIRO), 69120 Heidelberg, Germany.
  • Buchele C; National Center for Tumor Diseases (NCT), 69120 Heidelberg, Germany.
  • Schlüter F; Clinical Cooperation Unit Radiation Oncology, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
  • Rippke C; Department of Radiation Oncology, Heidelberg University Hospital, 69120 Heidelberg, Germany.
  • Renkamp CK; Heidelberg Institute of Radiation Oncology (HIRO), 69120 Heidelberg, Germany.
  • Weykamp F; National Center for Tumor Diseases (NCT), 69120 Heidelberg, Germany.
  • Regnery S; Department of Radiation Oncology, Heidelberg University Hospital, 69120 Heidelberg, Germany.
  • Liermann J; Heidelberg Institute of Radiation Oncology (HIRO), 69120 Heidelberg, Germany.
  • Meixner E; National Center for Tumor Diseases (NCT), 69120 Heidelberg, Germany.
  • Hoeltgen L; Department of Radiation Oncology, Heidelberg University Hospital, 69120 Heidelberg, Germany.
  • Eichkorn T; Heidelberg Institute of Radiation Oncology (HIRO), 69120 Heidelberg, Germany.
  • König L; National Center for Tumor Diseases (NCT), 69120 Heidelberg, Germany.
  • Debus J; Department of Radiation Oncology, Heidelberg University Hospital, 69120 Heidelberg, Germany.
  • Klüter S; Heidelberg Institute of Radiation Oncology (HIRO), 69120 Heidelberg, Germany.
  • Hörner-Rieber J; National Center for Tumor Diseases (NCT), 69120 Heidelberg, Germany.
Cancers (Basel) ; 16(12)2024 Jun 19.
Article en En | MEDLINE | ID: mdl-38927978
ABSTRACT
(1)

Background:

Recent publications foster stereotactic body radiotherapy (SBRT) in patients with adrenal oligometastases or oligoprogression. However, local control (LC) after non-adaptive SBRT shows the potential for improvement. Online adaptive MR-guided SBRT (MRgSBRT) improves tumor coverage and organ-at-risk (OAR) sparing. Long-term results of adaptive MRgSBRT are still sparse. (2)

Methods:

Adaptive MRgSBRT was performed on a 0.35 T MR-Linac. LC, overall survival (OS), progression-free survival (PFS), overall response rate (ORR), and toxicity were assessed. (3)

Results:

35 patients with 40 adrenal metastases were analyzed. The median gross tumor volume was 30.6 cc. The most common regimen was 10 fractions at 5 Gy. The median biologically effective dose (BED10) was 75.0 Gy. Plan adaptation was performed in 98% of all fractions. The median follow-up was 7.9 months. One local failure occurred after 16.6 months, resulting in estimated LC rates of 100% at one year and 90% at two years. ORR was 67.5%. The median OS was 22.4 months, and the median PFS was 5.1 months. No toxicity > CTCAE grade 2 occurred. (4)

Conclusions:

LC and ORR after adrenal adaptive MRgSBRT were excellent, even in a cohort with comparably large metastases. A BED10 of 75 Gy seems sufficient for improved LC in comparison to non-adaptive SBRT.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Cancers (Basel) Año: 2024 Tipo del documento: Article País de afiliación: Alemania Pais de publicación: Suiza
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Cancers (Basel) Año: 2024 Tipo del documento: Article País de afiliación: Alemania Pais de publicación: Suiza